Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
Recommended dosage for wet form of FIP is 6mg/kg
[DOI] [PubMed] [Google Scholar] 7.Veljaa M, Krni , Braja K, Mildner B, Pavi-Sladoljev D, eveljevi-Jaran D et al
Gastrointestinal support: BPC-157's origin is in gastric research, and the earliest published studies focused on its potential protective relationship with gastrointestinal tissue
BPC-157naturally produced in humangastric juice, but is also found in
The mechanism of action isnt well understood, but its believed it doesnt affect the tendon tissue cells directly, but rather that either works by activating other repair cells that can help tendons or ligaments or making the human growth factor receptor on the repair cells more sensitive (3)
